Key statistics
As of last trade Alpha Tau Medical Ltd (DRTS:NAQ) traded at 7.58, -11.86% below its 52-week high of 8.60, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.89 |
|---|---|
| High | 7.79 |
| Low | 7.35 |
| Bid | 7.53 |
| Offer | 7.58 |
| Previous close | 7.76 |
| Average volume | 396.04k |
|---|---|
| Shares outstanding | 85.26m |
| Free float | 57.38m |
| P/E (TTM) | -- |
| Market cap | 661.65m USD |
| EPS (TTM) | -0.5212 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 20:00 GMT.
More ▼
- Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
- Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
- Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
- Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
- Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
- Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
- Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
- Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
- Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
More ▼
